Home Laboratory assessment of iron status in pregnancy
Article
Licensed
Unlicensed Requires Authentication

Laboratory assessment of iron status in pregnancy

  • Thomas Walsh , Sean D. O'Broin EMAIL logo , Sharon Cooley , Jennifer Donnelly , John Kennedy , Robert F. Harrison , Corinna McMahon and Michael Geary
Published/Copyright: June 1, 2011

Abstract

Background: Efforts to improve maternal nutrition during pregnancy prompted an observational study of the occurrence of maternal iron deficiency and its laboratory diagnosis in almost 500 pregnancies.

Methods: In this longitudinal study, the biochemical and haematological iron indices of women (n=492) attending a prenatal clinic in a Dublin maternity hospital were assessed at first booking (mean 15.9 weeks), and after 24 weeks, and 36 weeks of gestation. Full blood counts were measured. Serum ferritin (SF), zinc protoporphyrin (ZPP), and transferrin receptor (sTfR) concentrations were assayed and transferrin receptor index (sTfR-Index) was calculated. The occurrence of low values and their diagnostic values were considered.

Results: A high occurrence iron deficiency (ID) at first booking (SF<12 μg/L) had increased over six-fold by 24 weeks, and all biochemical iron indices reflected progressive iron depletion right up to term. The WHO recommended anaemia “cut-off” (Hb<110 g/L) was insensitive to biochemical iron deficiency at booking, missing over 90% of the low SF values (SF<12 μg/L) which were mostly associated with much higher Hb levels.

Conclusions: This study stresses the importance of including a biochemical index of iron status in prenatal screening and supports SF as the best indicator of biochemical ID overall. sTfR was insensitive to iron deficiency in early pregnancy, whereas the sTfR-Index, as a ratio, has the potential to distinguish between ID and physiological anaemia, and may offer stability in the assessment of iron stores from early pregnancy to full term. A policy of early screening of both Hb and SF concentrations is recommended as the minimum requirement for surveillance of maternal iron status in pregnancy.


Corresponding author: Sean D. O'Broin, Department of Haematology, St James's Hospital, Dublin 8, Ireland Phone: +353-1-4162950

Received: 2010-10-7
Accepted: 2011-2-17
Published Online: 2011-06-1
Published in Print: 2011-07-01

©2011 by Walter de Gruyter Berlin Boston

Articles in the same Issue

  1. Editorial
  2. Method comparison: where do we draw the line?
  3. Review
  4. Current role of liquid chromatography coupled to mass spectrometry in clinical toxicology screening methods
  5. Minireview
  6. Molecular diagnostics for pharmacogenomic testing of fluoropyrimidine based-therapy: costs, methods and applications
  7. Opinion Paper
  8. Preanalytical quality improvement: from dream to reality
  9. Point
  10. Towards more complete specifications for acceptable analytical performance – a plea for error grid analysis
  11. Counterpoint
  12. Closing the brain-to-brain loop in laboratory testing
  13. General Clinical Chemistry and Laboratory Medicine
  14. Harmonization of growth hormone measurements with different immunoassays by data adjustment
  15. Comparison of the results from two different External Quality Assessment Schemes supports the utility of robust quality specifications
  16. High-throughput LC-MS/MS method for monitoring sirolimus and everolimus in the routine clinical laboratory
  17. Performance of the Roche Total Mycophenolic Acid® assay on the Cobas Integra 400®, Cobas 6000® and comparison to LC-MS/MS in liver transplant patients
  18. Diagnostic efficiency of truncated area under the curve from 0 to 2 h (AUC0–2) of mycophenolic acid in kidney transplant recipients receiving mycophenolate mofetil and concomitant tacrolimus
  19. Good performance of an immunoassay based method for nevirapine measurements in human breast milk
  20. Measurement of plasma amino acids by Ultraperformance® Liquid Chromatography
  21. Interchangeability of blood gas, electrolyte and metabolite results measured with point-of-care, blood gas and core laboratory analyzers
  22. Granularity Index of the SYSMEX XE-5000 hematology analyzer as a replacement for manual microscopy of toxic granulation neutrophils in patients with inflammatory diseases
  23. Direct chromogenic substrate immuno-capture activity assay for testing of factor VII-activating protease
  24. The antinuclear antibody assay: developing criteria for reflexive anti-dsDNA antibody testing in a laboratory setting
  25. A simple liquid chromatography-tandem mass spectrometry method for measuring metanephrine and normetanephrine in urine
  26. Monoclonal gammopathy missed by capillary zone electrophoresis
  27. Adaptation of the Diazyme Direct Enzymatic HbA1c Assay for a microplate reader at room temperature
  28. Validation and Outcome Studies
  29. Laboratory assessment of iron status in pregnancy
  30. Cardiovascular Diseases
  31. Blood cells characteristics as determinants of acute myocardial infarction
  32. No evidence for an association between the rs2824292 variant at chromosome 21q21 and ventricular fibrillation during acute myocardial infarction in a German population
  33. Letters to the Editor
  34. Letter to the Editor Reply: Statistical methods for assessment of added usefulness of new biomarkers
  35. Reply to Vavrova et al. Clin Chem Lab Med 2011;49:89–92
Downloaded on 28.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2011.187/html
Scroll to top button